Page 15 - reflections_newsletter

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #11 2026

10. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. Marston NA, et al. N Engl J Med. 2026 Jan
29;394(5):429-441. Dyslipidaemia

11. Great debate: Fire-and-forget beats personalized lipid-lowering treatment. Tokgozoglu L, et al. Eur Heart J. 2025 Nov
21;46(44):4751-4761.

12. Assessment of adverse effects attributed to statin therapy in product labels: A meta-analysis of double-
blind randomised controlled trials. Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet. 2026 Feb
14;407(10529):689-703.

SPECIAL POPULATIONS

13. Remnant cholesterol as an independent cardiovascular risk factor in young adults: An age-stratified cohort
study. Jung HN, et al. J Am Coll Cardiol. 2025 Nov 25;86(21):2047-2058.

14. Elevated lipoprotein(a) in patients with premature atherosclerotic cardiovascular disease: Insights from a large
US real-world cohort. Hu X, et al. J Clin Lipidol. 2025 Nov 28:S1933-2874(25)00522-7. doi: 10.1016/j.jacl.2025.11.015.
Online ahead of print.

15. Impact of obicetrapib on major adverse cardiovascular events in high-risk patients: A pooled analysis. Nicholls
SJ, et al. J Am Coll Cardiol. 2025 Oct 7;86(14):1046-1056.

Abbreviations
apoA-I, apolipoprotein A-I; apoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; ASO, antisense oligonucleotide;
ATP, adenosine triphosphate; BP, blood pressure; CAVS, calcific aortic valve stenosis; CETP, cholesteryl ester transfer protein;
CHD, coronary heart disease; CI, confidence interval; CoCoPop, condition context population; CRISPR, clustered regularly
interspaced short palindromic repeats; CV, cardiovascular; CVD, cardiovascular disease; CVOT, CV outcome trials; DBP, diastolic
blood pressure; DM, diabetes mellitus; EmCAD, Emory Cardiovascular Biobank; FBG, fasting blood glucose; HDL-C, high-
density lipoprotein cholesterol; HF, heart failure; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; HR, hazard ratio; HTG,
hypertriglyceridaemia; KNHIS, Korean National Health Insurance Service; LDL-C, low-density lipoprotein cholesterol; LDLR,
low-density lipoprotein receptor; Lp(a), lipoprotein(a); MACE, major adverse cardiovascular event; MESA, Multi-Ethnic Study of
Atherosclerosis; MI, myocardial infarction; mRNA, messenger ribonucleic acid; NHANES, National Health and Nutrition Examination
Survey; PCSK9, proprotein convertase subtilisin/kexin type 9; RF, risk factor; SBP, systolic blood pressure; sHTG, severe
hypertriglyceridaemia; siRNA, small interfering ribonucleic acid; SMuRFs, standard modifiable cardiovascular risk factors; TC, total
cholesterol; TG, triglycerides; UKB, United Kingdom Biobank; US, United States.

TABLE OF CONTENTS